Funxional Successfully Completes Initial Clinical Trial of FX125L
News Jul 13, 2009
Funxional Therapeutics Ltd (Funxional) has announced the successful completion of the first Phase I study with FX125L, an orally available small molecule which belongs to a new therapeutic class named Broad Spectrum Chemokine Inhibitors (BSCIs).
The Phase I, single ascending dose study was conducted in the United States. FX125L was well tolerated at all doses studied and no serious adverse events or subject withdrawals were observed. The pharmacokinetics of FX125L was linear over the wide dose range studied and consistent with once-daily oral dosing for patients.
“We are extremely pleased with the outcome of this initial clinical study with FX125L” said Konstantinos Efthymiopoulos, CEO of Funxional Therapeutics. “The results in humans are consistent with the preclinical data, suggesting that FX125L has a very wide safety margin, and confirmed the excellent drug-like profile of FX125L”.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019